4.5 Article

Epidemiology of the Rheumatic Diseases in Mexico. A Study of 5 Regions Based on the COPCORD Methodology

Journal

JOURNAL OF RHEUMATOLOGY
Volume 38, Issue -, Pages 3-8

Publisher

J RHEUMATOL PUBL CO
DOI: 10.3899/jrheum.100951

Keywords

EPIDEMIOLOGY; MEXICO; RHEUMATIC DISEASE; COPCORD METHODOLOGY

Categories

Funding

  1. Consejo Nacional de Ciencia y Tecnologia (CONACYT, National Council on Science and Technology)
  2. Abbot
  3. Novartis
  4. Roche
  5. Sanofi-Aventis
  6. Schering-Plough

Ask authors/readers for more resources

Objective. To estimate the prevalence of musculoskeletal (MSK) disorders and to describe predicting variables associated with rheumatic diseases in 5 regions of Mexico. Methods. This was a cross-sectional, community-based study performed in 5 regions in Mexico. The methodology followed the guidelines proposed by the Community Oriented Program for the Control of the Rheumatic Diseases (COPCORD). A standardized methodology was used at all sites, with trained personnel following a common protocol of interviewing adult subjects in their household. A positive case was defined as an individual with nontraumatic MSK pain of > 1 on a visual analog pain scale (0 to 10) during the last 7 days. All positive cases were referred to internists or rheumatologists for further clinical evaluation, diagnosis, and proper treatment. Results. The study included 19,213 individuals; 11,602 (68.8%) were female, and their mean age was 42.8 (SD 17.9) years. The prevalence of MSK pain was 25.5%, but significant variations (7.1% to 43.5%) across geographical regions occurred. The prevalence of osteoarthritis was 10.5%, back pain 5.8%, rheumatic regional pain syndromes 3.8%, rheumatoid arthritis 1.6%, fibromyalgia 0.7%, and gout 0.3%. The prevalence of MSK manifestations was associated with older age and female gender. Conclusion. The prevalence of MSK pain in our study was 25.5%. Geographic variations in the prevalence of MSK pain and specific diagnoses suggested a role for geographic factors in the prevalence of rheumatic diseases. (J Rheumatol 2011;38 Suppl 86:3-6; doi:10.3899/jrheum.100951)

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available